Pharmaceutical Supply Chain Risk Assessment Act of 2023

S 1961, the Pharmaceutical Supply Chain Risk Assessment Act of 2023, requires the Department of Health and Human Services (HHS) to lead an annual assessment of the U.S. pharmaceutical supply chain, working with the Departments of Defense and Homeland Security. The assessment must identify essential medicines critical for public health emergencies or national security, evaluate vulnerabilities like foreign sourcing of ingredients, cybersecurity risks, and gaps in domestic manufacturing capabilities. It will report findings to Congress within 18 months of enactment, with annual updates, and make the results publicly available (excluding sensitive classified details). This bill directly affects federal agencies managing supply chains and aims to strengthen national health security through systematic risk analysis.